Cargando…

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai

The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Ziyu, Liang, Dongguo, Zhang, Wei, Shi, Dongling, Ma, Yuhua, Wei, Dong, Xi, Junxiang, Yang, Sizhe, Xu, Xiaoguang, Tian, Di, Zhu, Zhaoqing, Guo, Mingquan, Jiang, Lu, Yu, Shuting, Wang, Shuai, Jiang, Fangyin, Ling, Yun, Wang, Shengyue, Chen, Saijuan, Liu, Feng, Tan, Yun, Fan, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033297/
https://www.ncbi.nlm.nih.gov/pubmed/36949347
http://dx.doi.org/10.1007/s11684-022-0977-3
_version_ 1784910983460814848
author Fu, Ziyu
Liang, Dongguo
Zhang, Wei
Shi, Dongling
Ma, Yuhua
Wei, Dong
Xi, Junxiang
Yang, Sizhe
Xu, Xiaoguang
Tian, Di
Zhu, Zhaoqing
Guo, Mingquan
Jiang, Lu
Yu, Shuting
Wang, Shuai
Jiang, Fangyin
Ling, Yun
Wang, Shengyue
Chen, Saijuan
Liu, Feng
Tan, Yun
Fan, Xiaohong
author_facet Fu, Ziyu
Liang, Dongguo
Zhang, Wei
Shi, Dongling
Ma, Yuhua
Wei, Dong
Xi, Junxiang
Yang, Sizhe
Xu, Xiaoguang
Tian, Di
Zhu, Zhaoqing
Guo, Mingquan
Jiang, Lu
Yu, Shuting
Wang, Shuai
Jiang, Fangyin
Ling, Yun
Wang, Shengyue
Chen, Saijuan
Liu, Feng
Tan, Yun
Fan, Xiaohong
author_sort Fu, Ziyu
collection PubMed
description The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. Compared to an earlier patient cohort infected by SARS-CoV-2 prototype strains in 2020, BA.2.2 infection led to distinct fluctuations of pathophysiological markers in the peripheral blood. In particular, severe/critical cases of COVID-19 post BA.2.2 infection were associated with less pro-inflammatory macrophage activation and stronger interferon alpha response in the bronchoalveolar microenvironment. Importantly, the abnormal biomarkers were significantly subdued in individuals who had been immunized by 2 or 3 doses of SARS-CoV-2 prototype-inactivated vaccines, supporting the estimation of an overall 96.02% of protection rate against severe/critical disease in the 4854 cases in our BA.2.2 patient cohort with traceable vaccination records. Furthermore, even though age was a critical risk factor of the severity of COVID-19 post BA.2.2 infection, vaccination-elicited protection against severe/critical COVID-19 reached 90.15% in patients aged ≽ 60 years old. Together, our study delineates the pathophysiological features of Omicron BA.2.2 sublineages and demonstrates significant protection conferred by prior prototype-based inactivated vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available in the online version of this article at 10.1007/s11684-022-0977-3 and is accessible for authorized users.
format Online
Article
Text
id pubmed-10033297
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Higher Education Press
record_format MEDLINE/PubMed
spelling pubmed-100332972023-03-23 Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai Fu, Ziyu Liang, Dongguo Zhang, Wei Shi, Dongling Ma, Yuhua Wei, Dong Xi, Junxiang Yang, Sizhe Xu, Xiaoguang Tian, Di Zhu, Zhaoqing Guo, Mingquan Jiang, Lu Yu, Shuting Wang, Shuai Jiang, Fangyin Ling, Yun Wang, Shengyue Chen, Saijuan Liu, Feng Tan, Yun Fan, Xiaohong Front Med Research Article The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. Compared to an earlier patient cohort infected by SARS-CoV-2 prototype strains in 2020, BA.2.2 infection led to distinct fluctuations of pathophysiological markers in the peripheral blood. In particular, severe/critical cases of COVID-19 post BA.2.2 infection were associated with less pro-inflammatory macrophage activation and stronger interferon alpha response in the bronchoalveolar microenvironment. Importantly, the abnormal biomarkers were significantly subdued in individuals who had been immunized by 2 or 3 doses of SARS-CoV-2 prototype-inactivated vaccines, supporting the estimation of an overall 96.02% of protection rate against severe/critical disease in the 4854 cases in our BA.2.2 patient cohort with traceable vaccination records. Furthermore, even though age was a critical risk factor of the severity of COVID-19 post BA.2.2 infection, vaccination-elicited protection against severe/critical COVID-19 reached 90.15% in patients aged ≽ 60 years old. Together, our study delineates the pathophysiological features of Omicron BA.2.2 sublineages and demonstrates significant protection conferred by prior prototype-based inactivated vaccines. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary material is available in the online version of this article at 10.1007/s11684-022-0977-3 and is accessible for authorized users. Higher Education Press 2023-03-23 /pmc/articles/PMC10033297/ /pubmed/36949347 http://dx.doi.org/10.1007/s11684-022-0977-3 Text en © Higher Education Press 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Research Article
Fu, Ziyu
Liang, Dongguo
Zhang, Wei
Shi, Dongling
Ma, Yuhua
Wei, Dong
Xi, Junxiang
Yang, Sizhe
Xu, Xiaoguang
Tian, Di
Zhu, Zhaoqing
Guo, Mingquan
Jiang, Lu
Yu, Shuting
Wang, Shuai
Jiang, Fangyin
Ling, Yun
Wang, Shengyue
Chen, Saijuan
Liu, Feng
Tan, Yun
Fan, Xiaohong
Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
title Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
title_full Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
title_fullStr Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
title_full_unstemmed Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
title_short Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai
title_sort host protection against omicron ba.2.2 sublineages by prior vaccination in spring 2022 covid-19 outbreak in shanghai
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033297/
https://www.ncbi.nlm.nih.gov/pubmed/36949347
http://dx.doi.org/10.1007/s11684-022-0977-3
work_keys_str_mv AT fuziyu hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT liangdongguo hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT zhangwei hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT shidongling hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT mayuhua hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT weidong hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT xijunxiang hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT yangsizhe hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT xuxiaoguang hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT tiandi hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT zhuzhaoqing hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT guomingquan hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT jianglu hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT yushuting hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT wangshuai hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT jiangfangyin hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT lingyun hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT wangshengyue hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT chensaijuan hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT liufeng hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT tanyun hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai
AT fanxiaohong hostprotectionagainstomicronba22sublineagesbypriorvaccinationinspring2022covid19outbreakinshanghai